10299-44-2
Chemical Structure
8-Azaadenosine
- CAS No.: 10299-44-2
- Formula:C9H12N6O4
- Molecular Weight:268.23
IUPAC Name: (2R,3R,4S,5R)-2-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
InChIKey: OAUKGFJQZRGECT-UUOKFMHZSA-N
SMILES: NC1=NC=NC2=C1N=NN2[C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO
Biological Activity: 8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
8-Azaadenosine | 99.94% | 8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Maria Anna Zipeto, et al. ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell. 2016 Aug 4;19(2):177-191. [Content Brief]
- [2]. Julia Ramírez-Moya, et al. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity. Oncogene. 2020 Apr;39(18):3738-3753. [Content Brief]
Keywords